EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting N-Methyl-d-Aspartate Receptors in Neurodegenerative Diseases

Allison Carles iD, Aline Freyssin, Florent Perin-Dureau, Gilles Rubinstenn iD, Tangui Maurice iD

International Journal of Molecular Sciences · 27.03.2024 · 25 (7) · 3733

DOI: 10.3390/ijms25073733 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.03.2024. Verfasst von Allison Carles und 4 weiteren Autor:innen. Beteiligte Einrichtung: MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Alzheimer Disease, Parkinson Disease. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SATT AXLR, REST THERAPEUTICS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N-methyl-d-aspartate receptors (NMDARs) are the main class of ionotropic receptors for the excitatory neurotransmitter glutamate. They play a crucial role in the permeability of Ca2+ ions and excitatory neurotransmission in the brain. Being heteromeric receptors, they are composed of several subunits, including two obligatory GluN1 subunits (eight splice variants) and regulatory GluN2 (GluN2A~D) or GluN3 (GluN3A~B) subunits. Widely distributed in the brain, they regulate other neurotransmission systems and are therefore involved in essential functions such as synaptic transmission, learning and memory, plasticity, and excitotoxicity. The present review will detail the structure, composition, and localization of NMDARs, their role and regulation at the glutamatergic synapse, and their impact on cognitive processes and in neurodegenerative diseases (Alzheimer’s, Huntington’s, and Parkinson’s disease). The pharmacology of different NMDAR antagonists and their therapeutic potentialities will be presented. In particular, a focus will be given on fluoroethylnormemantine (FENM), an investigational drug with very promising development as a neuroprotective agent in Alzheimer’s disease, in complement to its reported efficacy as a tomography radiotracer for NMDARs and an anxiolytic drug in post-traumatic stress disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurodegenerative DiseasesAlzheimer DiseaseParkinson DiseaseHumansReceptors, N-Methyl-D-AspartateGlutamic Acid

Stichwörter der Autor:innen

Alzheimer’s diseaseN-methyl-d-aspartate receptorfluoroethylnormemantine (FENM)neurodegenerative diseases

Substanzen

Receptors, N-Methyl-D-AspartateGlutamic Acid

Autor:innen und Institutionen

  • MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
  • ReST Therapeutics, 34095 Montpellier, France.

ORCID-Profile: Allison Carles, Gilles Rubinstenn, Tangui Maurice

Förderung

  • SATT AXLR
  • REST THERAPEUTICS

Zitieren

APA

Carles, A., Freyssin, A., Perin-Dureau, F., Rubinstenn, G., & Maurice, T. (2024). Targeting N-Methyl-d-Aspartate Receptors in Neurodegenerative Diseases. International Journal of Molecular Sciences, 25(7), 3733. https://doi.org/10.3390/ijms25073733

Vancouver

Carles A, Freyssin A, Perin-Dureau F, Rubinstenn G, Maurice T. Targeting N-Methyl-d-Aspartate Receptors in Neurodegenerative Diseases. International Journal of Molecular Sciences. 2024;25(7):3733. doi:10.3390/ijms25073733

BibTeX
@article{Carles2024,
  author = {Carles, Allison and Freyssin, Aline and Perin-Dureau, Florent and Rubinstenn, Gilles and Maurice, Tangui},
  title = {Targeting N-Methyl-d-Aspartate Receptors in Neurodegenerative Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {7},
  pages = {3733},
  doi = {10.3390/ijms25073733}
}
Kostenlos starten →